18F-flubrobenguane PET显像在疑似嗜铬细胞瘤或副神经节瘤患者的首次应用体验
该回顾性分析纳入23例疑似嗜铬细胞瘤或副神经节瘤患者,注射18F-flubrobenguane后行PET/CT或PET/MRI,评估其生物分布及对肿瘤病灶的检出能力。结果显示该示踪剂生物分布可重复且稳定,肿瘤病灶摄取高,且PET融合显像较传统影像报告了更多、更小的病灶并具有更高诊断确定性,但未达统计学显著性。初步提示18F-flubrobenguane PET是疑似嗜铬细胞瘤或副神经节瘤的有效分期工具。
要点
- 18F-flubrobenguane生物分布稳定,甲状腺、胰腺和肿瘤病灶摄取最高。
- 肿瘤病灶平均SUVmax为16.8±1.7,平均SUVmean为10.1±1.1。
- 小于1cm的23个病灶中,61%(14/23)仅在PET融合显像上发现。
核心结论
- 初步数据提示18F-flubrobenguane PET是疑似嗜铬细胞瘤或副神经节瘤的新有效分期工具,主要优势为快速采集、高空间分辨率和肿瘤病灶高摄取。
- 需进一步研究明确18F-flubrobenguane PET的作用,尤其是与MRI或123I-MIBG SPECT/CT等标准诊断程序比较。
研究设计与样本
- 回顾性分析纳入23例疑似嗜铬细胞瘤或副神经节瘤患者,注射18F-flubrobenguane后行PET/CT或PET/MRI。
- 注射后63±24分钟采集,注射剂量256±33 MBq,测量器官SUVmean和SUVmax及肿瘤病灶SUV。
- 一名阅片者分别评估所有横断面影像(CT或MRI)及PET融合数据集,报告病灶数量和大小,并以3分制评分阳性病灶的诊断确定性。
主要发现
- 18F-flubrobenguane显示可重复且稳定的生物分布,甲状腺SUVmax和SUVmean最高(30.3±2.2和22.5±1.6),胰腺(12.2±0.8和9.5±0.7),肿瘤病灶(16.8±1.7和10.1±1.1),肌肉最低(1.1±0.06和0.7±0.04),肺(2.5±0.17和1.85±0.13)。
- 亚组分析显示嗜铬细胞瘤和副神经节瘤的平均SUVmean均显著高于健康肾上腺(分别为11.9±2.0 vs. 9.9±1.5 vs. 3.7±0.2)。
- 共检测47个病灶,PET融合显像较传统影像报告了更多、更小的病灶且诊断确定性更高,但未达统计学显著性。
- 23个小于1cm的病灶中,61%(14/23)仅在融合显像上发现。
关键数值与推荐
- 甲状腺SUVmax 30.3±2.2、SUVmean 22.5±1.6;胰腺SUVmax 12.2±0.8、SUVmean 9.5±0.7;肿瘤病灶SUVmax 16.8±1.7、SUVmean 10.1±1.1;肌肉SUVmax 1.1±0.06、SUVmean 0.7±0.04;肺SUVmax 2.5±0.17、SUVmean 1.85±0.13。
- 嗜铬细胞瘤、副神经节瘤和健康肾上腺的平均SUVmean分别为11.9±2.0、9.9±1.5和3.7±0.2,嗜铬细胞瘤和副神经节瘤均显著高于健康肾上腺。
- 共47个病灶,其中小于1cm者23个(23/47,49%),这23个中61%(14/23)仅在融合显像上发现。
临床怎么用
- 对疑似嗜铬细胞瘤或副神经节瘤患者,18F-flubrobenguane PET融合显像可检出更多小病灶并提高诊断确定性,尤其有助于发现小于1cm的病灶。
- 阅片时应注意甲状腺和胰腺的高生理性摄取,避免误判。
局限性
- 本研究为回顾性分析,样本量有限(23例),结果属初步数据。
- PET融合显像较传统影像报告更多更小病灶且诊断确定性更高,但未达统计学显著性。
- 尚未与MRI或123I-MIBG SPECT/CT等标准诊断程序进行对比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pheochromocytomas and paragangliomas are a rare tumor entity originating from adrenomedullary chromaffin cells in the adrenal medulla or in sympathetic, paravertebral ganglia outside the medulla. Small lesions are especially difficult to detect by conventional CT or MRI and even by SPECT with the currently available radiotracers (e.g., metaiodobenzylguanidine [MIBG]). The novel PET radiotracer 18F-flubrobenguane could change the diagnostic paradigm in suspected pheochromocytomas and paragangliomas because of its homology with MIBG and the general advantages of PET imaging. The aim of this retrospective analysis was to evaluate 18F-flubrobenguane in pheochromocytomas and paragangliomas and to investigate the biodistribution in patients. Methods: Twenty-three patients with suspected pheochromocytoma or paraganglioma underwent PET/CT or PET/MRI at 63 ± 24 min after injection of 256 ± 33 MBq of 18F-flubrobenguane. The SUVmean and SUVmax of organs were measured with spheric volumes of interest. Threshold-segmented volumes of interest were used to measure the SUVmean or SUVmax of the tumor lesions. One reader evaluated all cross-sectional imaging datasets (CT or MRI) separately, as well as the PET hybrid datasets, and reported the lesion number and size. The diagnostic certainty for a positive lesion was scored on a 3-point scale. Results:18F-flubrobenguane showed a reproducible, stable biodistribution, with the highest SUVmax and SUVmean being in the thyroid gland (30.3 ± 2.2 and 22.5 ± 1.6, respectively), pancreas (12.2 ± 0.8 and 9.5 ± 0.7, respectively), and tumor lesions (16.8 ± 1.7 and 10.1 ± 1.1, respectively) and the lowest SUVmax and SUVmean being in muscle (1.1 ± 0.06 and 0.7 ± 0.04, respectively) and the lung (2.5 ± 0.17 and 1.85 ± 0.13, respectively). In a subgroup analysis, a significantly higher average SUVmean was seen for both pheochromocytoma and paraganglioma than for healthy adrenal glands (11.9 ± 2.0 vs. 9.9 ± 1.5 vs. 3.7 ± 0.2, respectively). In total, 47 lesions were detected. The reader reported more and smaller lesions with higher certainty in PET hybrid imaging than in conventional imaging; however, statistical significance was not reached. Of the 23 (23/47, 49%) lesions smaller than 1 cm, 61% (14/23) were found on hybrid imaging only. Conclusion: Our preliminary data suggest 18F-flubrobenguane PET to be a new, effective staging tool for patients with suspected pheochromocytoma or paraganglioma. Major advantages are the fast acquisition and high spatial resolution of PET imaging and the intense uptake in tumor lesions, facilitating detection. Further studies are warranted to define the role of 18F-flubrobenguane PET, particularly in comparison to standard diagnostic procedures such as MRI or 123I-MIBG SPECT/CT.
引用
- Kessler L, Schlitter AM, Krönke M, et al. First Experience Using 18F-Flubrobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma. J Nucl Med. 2020. PMID: 32859709. doi:10.2967/jnumed.120.248021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。